Q-omics provides the consensus-scored ERAS profile across patient tissues and cancer cell-line models. ERAS expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ERAS is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, ERAS RNA expression shows 13,470 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight KIRC, KICH, and SARC as cancer lineages where ERAS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERAS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERAS survival associations across molecular data types. ERAS RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERAS RNA expression–survival associations across cancer types. High ERAS expression shows unfavorable associations in KIRC, ACC, LIHC and PRAD, but favorable associations in UVM and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRC as the clearest survival context for ERAS RNA expression.
This table summarizes ERAS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ERAS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERAS shows lower tumor expression in KICH and higher tumor expression in UCEC, BLCA, HNSC, CHOL and LUAD. The KICH box plot shows higher ERAS RNA expression in normal versus tumor tissue (log2 FC = −0.206, t-test p < 0.001).
This table shows molecular features associated with ERAS in patient tissues and cancer cell lines. In patient samples, ERAS shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, ERAS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LUNG_SCLC.
